Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONCERTO-2: Simeprevir + PR in HCV Genotype 1 Non-Responders
NCT01288209Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2011
- Primary completion
- Sep 2012
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of simeprevir in hepatitis C virus infection, sponsored by Janssen Pharmaceutical. Started Feb 2011; status: completed.
02
Drugs
simeprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT01288209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01288209.